AbbVie's Life After Abbott Motley Fool One of the drugs the company pins future hopes on is daclizumab, which is used to treat relapsing multiple sclerosis. A phase 3 clinical trial is currently under way for the drug in collaboration with Biogen (NASDAQ: BIIB ) . Results from this study ... |
